Cyrcadia Health
Cyrcadia Health is a privately traded company based in Reno, Nevada, specializing in early breast cancer detection technology through a wearable device called the Cyrcadia Breast Monitor. This device uses intelligent, non-invasive, wearable breast patches embedded with temperature sensors to monitor circadian temperature changes in breast tissue, leveraging machine learning predictive analytics developed in partnership with Nanyang Technological University of Singapore. The system transmits data via Bluetooth to a mobile app and then to a cloud-based core lab for analysis, providing automated, reproducible results to healthcare providers. The technology is designed as an adjunct to traditional imaging methods, particularly effective for women with dense breast tissue, offering a radiation-free, comfortable, and affordable screening alternative suitable for mass screening and young women. Clinical trials have demonstrated high sensitivity and specificity, with the device detecting cancers missed by mammography, especially in dense breast tissue. Cyrcadia Health holds three patents related to its core circadian rhythm disruption science and continues to evolve its analytics framework. The product is not yet available for sale in the United States.
Cyrcadia Health
Cyrcadia Health is a privately traded company based in Reno, Nevada, specializing in early breast cancer detection technology through a wearable device called the Cyrcadia Breast Monitor. This device uses intelligent, non-invasive, wearable breast patches embedded with temperature sensors to monitor circadian temperature changes in breast tissue, leveraging machine learning predictive analytics developed in partnership with Nanyang Technological University of Singapore. The system transmits data via Bluetooth to a mobile app and then to a cloud-based core lab for analysis, providing automated, reproducible results to healthcare providers. The technology is designed as an adjunct to traditional imaging methods, particularly effective for women with dense breast tissue, offering a radiation-free, comfortable, and affordable screening alternative suitable for mass screening and young women. Clinical trials have demonstrated high sensitivity and specificity, with the device detecting cancers missed by mammography, especially in dense breast tissue. Cyrcadia Health holds three patents related to its core circadian rhythm disruption science and continues to evolve its analytics framework. The product is not yet available for sale in the United States.